West Pharmaceutical Services, Inc.
336.94USD
-0.8100 (-0.24%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.19▲ | $2.13 | 9 | 0 |
| Next quarter | $2.27▲ | $2.26 | 4 | 3 |
| Current year | $8.96▲ | $8.61 | 14 | 0 |
| Next year | $9.96▲ | $9.54 | 14 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.08 | $2.37 | +0.29 (+13.9%) |
| 2026-03-31 | $1.68 | $2.13 | +0.45 (+27.1%) |
| 2025-12-31 | $1.83 | $2.04 | +0.21 (+11.5%) |
| 2025-09-30 | $1.71 | $1.96 | +0.25 (+14.6%) |
81 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Buy | $340 $415 | Sep 9, 2026 |
| Citigroup | Maintained | Buy | $400 $412 | Aug 3, 2026 |
| Evercore ISI Group | Maintained | Outperform | $410 $425 | Jul 27, 2026 |
| BNP Paribas | Initiated | Outperform | $447 | Jul 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $325 $365 | Jul 9, 2026 |
| Evercore ISI Group | Maintained | Outperform | $390 $410 | Jul 6, 2026 |
| Keybanc | Maintained | Overweight | $350 $390 | Jul 2, 2026 |
| Barclays | Upgraded from Equal-Weight | Overweight | $310 $400 | Jun 9, 2026 |
| Stephens & Co. | Reiterated | Overweight | $360 | Jun 2, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $315 $325 | May 29, 2026 |
| Barclays | Maintained | Equal-Weight | $275 $310 | Apr 27, 2026 |
| Barclays | Maintained | Equal-Weight | $265 $275 | Apr 14, 2026 |
| Barclays | Maintained | Equal-Weight | $325 $265 | Feb 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $390 $320 | Feb 3, 2026 |
| Morgan Stanley | Initiated | Equal-Weight | $285 | Dec 2, 2025 |
| TD Cowen | Initiated | Buy | $350 | Oct 29, 2025 |
| Barclays | Maintained | Equal-Weight | $275 $325 | Oct 27, 2025 |
| UBS | Maintained | Buy | $320 $355 | Oct 24, 2025 |
| Keybanc | Maintained | Overweight | $325 $350 | Oct 24, 2025 |
| Evercore ISI Group | Maintained | Outperform | $350 $390 | Oct 23, 2025 |
| Barclays | Maintained | Equal-Weight | $260 $275 | Oct 2, 2025 |
| Rothschild & Co | Initiated | Buy | $311 | Sep 15, 2025 |
| UBS | Maintained | Buy | $285 $320 | Jul 25, 2025 |
| Evercore ISI Group | Maintained | Outperform | $275 $350 | Jul 25, 2025 |
| Barclays | Maintained | Equal-Weight | $245 $260 | Jul 25, 2025 |
50 filings from 22 insiders · 14 buy / 2 sell over 6m
Officers and directors of WST, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MCMAHON ROBERT WChief Financial Officer | Other | 7.1k | — | — | Aug 11, 2026 |
| CAMPBELL SHANE ALDENOfficer | Other | 769 | — | — | May 12, 2026 |
| HAUGEN JANET BRUTSCHEADirector | Grant | 791 | — | — | May 4, 2026 |
| LAI-GOLDMAN MYLA PDirector | Grant | 791 | — | — | May 4, 2026 |
| FRIEL ROBERT FDirector | Grant | 791 | — | — | May 4, 2026 |
| KELLER DEBORAH LDirector | Grant | 791 | — | — | May 4, 2026 |
| JOSEPH MOLLY E.Director | Grant | 791 | — | — | May 4, 2026 |
| LOCKHART STEPHEN HDirector | Grant | 791 | — | — | May 4, 2026 |
| BUTHMAN MARK ADirector | Grant | 791 | — | — | May 4, 2026 |
| PUCCI PAOLODirector | Grant | 791 | — | — | May 4, 2026 |
| FEEHERY WILLIAM F.Director | Grant | 791 | — | — | May 4, 2026 |
| MICHELS DOUGLAS ADirector | Grant | 791 | — | — | May 4, 2026 |
| FAVORITE ANNETTE FOfficer | Exercise | 2.8k | $83.47 | $235k | Apr 27, 2026 |
| WINTERS CHADOfficer | Exercise | 896 | $173.22 | $155k | Apr 27, 2026 |
| FAVORITE ANNETTE FOfficer | Sell | 2.8k | $305.20 | $860k | Apr 27, 2026 |
| WINTERS CHADOfficer | Sell | 896 | $300.67 | $269k | Apr 27, 2026 |
| WITHERSPOON CHARLESOfficer and Treasurer | Other | 60 | — | — | Feb 20, 2026 |
| WINTERS CHADOfficer | Other | 89 | — | — | Feb 20, 2026 |
| POUSSOT RODOLPHE JEANOfficer | Other | 383 | — | — | Feb 20, 2026 |
| FAVORITE ANNETTE FOfficer | Other | 135 | — | — | Feb 18, 2026 |
No analyst notes on WST yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 11 | 2 | 0 | 0 | Buy1.94 |
| 1 mo ago | 3 | 11 | 2 | 0 | 0 | Buy1.94 |
| 2 mo ago | 3 | 11 | 2 | 0 | 0 | Buy1.94 |
| 3 mo ago | 2 | 11 | 1 | 0 | 1 | Buy2.13 |